Literature DB >> 34673145

Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia.

Liu-Yun Wu1, Irwin K Cheah2, Joyce Ruifen Chong1, Yuek Ling Chai1, Jia Yun Tan2, Saima Hilal3, Henri Vrooman4, Christopher P Chen5, Barry Halliwell6, Mitchell K P Lai7.   

Abstract

Ergothioneine (ET) is a dietary amino-thione with strong antioxidant and cytoprotective properties and has possible therapeutic potential for neurodegenerative and vascular diseases. Decreased blood concentrations of ET have been found in patients with mild cognitive impairment, but its status in neurodegenerative and vascular dementias is currently unclear. To address this, a cross-sectional study was conducted on 496 participants, consisting of 88 with no cognitive impairment (NCI), 201 with cognitive impairment, no dementia (CIND) as well as 207 with dementia, of whom 160 have Alzheimer's Disease (AD) and 47 have vascular dementia. All subjects underwent blood-draw, neuropsychological assessments, as well as neuroimaging assessments of cerebrovascular diseases (CeVD) and brain atrophy. Plasma ET as well as its metabolite l-hercynine were measured using high sensitivity liquid chromatography tandem-mass spectrometry (LC-MS/MS). Plasma ET concentrations were lowest in dementia (p < 0.001 vs. NCI and CIND), with intermediate levels in CIND (p < 0.001 vs. NCI). A significant increase in l-hercynine to ET ratio was also observed in dementia (p < 0.01 vs. NCI). In multivariate models adjusted for demographic and vascular risk factors, lower levels of ET were significantly associated with dementia both with or without CeVD, while ET associations with CIND were significant only in the presence of CeVD. Furthermore, lower ET levels were also associated with white matter hyperintensities and brain atrophy markers (reduced global cortical thickness and hippocampal volumes). The incremental decreases in ET levels along the CIND-dementia clinical continuum suggest that low levels of ET are associated with disease severity and could be a potential biomarker for cognitive impairment. Deficiency of ET may contribute towards neurodegeneration- and CeVD-associated cognitive impairments, possibly via the exacerbation of oxidative stress in these conditions.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Biomarkers; Cerebrovascular diseases; Ergothioneine; Neurodegeneration; Vascular dementia

Mesh:

Substances:

Year:  2021        PMID: 34673145     DOI: 10.1016/j.freeradbiomed.2021.10.019

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  4 in total

Review 1.  Ergothioneine and central nervous system diseases.

Authors:  Noritaka Nakamichi; Sota Tsuzuku; Fumiya Shibagaki
Journal:  Neurochem Res       Date:  2022-07-05       Impact factor: 4.414

Review 2.  Blood-Based Biomarkers for Alzheimer's Disease Diagnosis and Progression: An Overview.

Authors:  Angelica Varesi; Adelaide Carrara; Vitor Gomes Pires; Valentina Floris; Elisa Pierella; Gabriele Savioli; Sakshi Prasad; Ciro Esposito; Giovanni Ricevuti; Salvatore Chirumbolo; Alessia Pascale
Journal:  Cells       Date:  2022-04-17       Impact factor: 7.666

3.  Reply to Zheng et al.: Clinical metabolomics: Detailed analysis by nontargeted method is complementary to large-scale studies.

Authors:  Hiroshi Kondoh; Takayuki Teruya; Yung-Ju Chen; Yasuhide Fukuji; Mitsuhiro Yanagida
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-01       Impact factor: 11.205

Review 4.  Horizons in Human Aging Neuroscience: From Normal Neural Aging to Mental (Fr)Agility.

Authors:  K Richard Ridderinkhof; Harm J Krugers
Journal:  Front Hum Neurosci       Date:  2022-06-29       Impact factor: 3.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.